

Vakaramoko Diaby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5387432/publications.pdf>

Version: 2024-02-01

55
papers

982
citations

566801

15
h-index

454577

30
g-index

60
all docs

60
docs citations

60
times ranked

1445
citing authors

#	ARTICLE	IF	CITATIONS
1	Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis. <i>Health Expectations</i> , 2015, 18, 1894-1905.	1.1	142
2	Multi-criteria decision analysis (MCDA) in health care: A bibliometric analysis. <i>Operations Research for Health Care</i> , 2013, 2, 20-24.	0.8	135
3	A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 27-40.	1.1	110
4	Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. <i>Value in Health</i> , 2019, 22, 1283-1288.	0.1	97
5	How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 81-99.	0.7	52
6	Sedative-Hypnotic Medicines and Falls in Community-Dwelling Older Adults: A Cost-Effectiveness (Decision-Tree) Analysis from a US Medicare Perspective. <i>Drugs and Aging</i> , 2015, 32, 305-314.	1.3	49
7	Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 187-196.	1.1	35
8	Multicriteria decision analysis in oncology. <i>Health Expectations</i> , 2015, 18, 1812-1826.	1.1	32
9	Introduction to health economics and decision-making: Is economics relevant for the frontline clinician?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 831-844.	1.0	25
10	Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. <i>Pharmacogenomics Journal</i> , 2020, 20, 724-735.	0.9	25
11	Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 13-19.	0.7	20
12	Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 433-441.	1.1	17
13	Value Assessment Frameworks in the United States: A Call for Patient Engagement. <i>PharmacoEconomics - Open</i> , 2019, 3, 1-3.	0.9	17
14	An Application of a Proposed Framework for Formulary Listing in Low-Income Countries. <i>Applied Health Economics and Health Policy</i> , 2011, 9, 389-402.	1.0	16
15	Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada. <i>PLoS ONE</i> , 2016, 11, e0162951.	1.1	16
16	Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States. <i>Pharmacogenomics Journal</i> , 2022, 22, 223-229.	0.9	15
17	Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. <i>Current Medical Research and Opinion</i> , 2016, 32, 991-996.	0.9	14
18	Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 669-673.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 951-963.	1.1	13
20	Timing, Costs, and Survival Outcome of Specialty Palliative Care in Medicare Beneficiaries With Metastatic Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2020, 16, e1532-e1542.	1.4	11
21	A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. <i>Breast</i> , 2020, 49, 141-148.	0.9	10
22	ELICIT: An alternative imprecise weight elicitation technique for use in multi-criteria decision analysis for healthcare. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 141-147.	0.7	8
23	Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. <i>Current Medical Research and Opinion</i> , 2017, 33, 391-400.	0.9	8
24	Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 826-831.	0.5	8
25	Eliciting Preferences for Reimbursed Drugs Selection Criteria in Cote d'Ivoire. <i>Patient</i> , 2011, 4, 125-131.	1.1	7
26	Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data. <i>Cancer Medicine</i> , 2019, 8, 117-127.	1.3	7
27	Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders. <i>American Journal of Preventive Medicine</i> , 2021, 61, 576-584.	1.6	7
28	A quantitative analysis of the effect of continuity of care on 30-day readmission and in-hospital mortality among patients with acute ischemic stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105053.	0.7	6
29	Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States. <i>JCO Oncology Practice</i> , 2021, , OP.21.00140.	1.4	6
30	An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review. <i>Current Diabetes Reviews</i> , 2018, 14, 363-375.	0.6	6
31	An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 142-152.	0.5	5
32	Examining factors associated with adherence to hormonal therapy in breast cancer patients. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 574-582.	1.5	5
33	Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 353-364.	0.7	5
34	A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 159-168.	0.7	5
35	Identification of risk factors of 30-day readmission and 180-day in-hospital mortality, and its corresponding relative importance in patients with Ischemic heart disease: a machine learning approach. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 1043-1048.	0.7	4
36	Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 679-687.	1.0	4

#	ARTICLE	IF	CITATIONS
37	Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1095-1099.	1.5	3
38	Self-assessed life expectancy among older adults in CÔte d'Ivoire. <i>BMC Public Health</i> , 2020, 20, 932.	1.2	3
39	Prevalence and effects of suicidal ideation diagnosis code position in claims on readmission rate estimates. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1174-1180.	1.5	3
40	Evaluation of statin discontinuation stratified by primary versus secondary prevention following bariatric surgery: a retrospective cohort study. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 939-946.	1.0	3
41	Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women. <i>Maturitas</i> , 2007, 58, 138-149.	1.0	2
42	In our war against the opioid epidemic, could "weed" be a winner?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 423-429.	0.7	2
43	Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1388-1402.	0.5	2
44	Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 735-741.	0.7	2
45	Improving Health Care Decision Making in the USA Through Comparative Effectiveness Research: The Role of Economic Evaluation. <i>Pharmaceutical Medicine</i> , 2015, 29, 247-253.	1.0	1
46	Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting. <i>Data in Brief</i> , 2020, 29, 105194.	0.5	1
47	Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 923-941.	0.7	1
48	Effects, trends, costs associated with readmission in early-aged patients with suicidal ideation. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, , 1-12.	0.7	1
49	Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 409-415.	0.7	1
50	Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, S22-S29.	0.5	1
51	Exploring the state of pharmacy profession: The perspective of CÔte d'Ivoire. <i>Currents in Pharmacy Teaching and Learning</i> , 2013, 5, 470-476.	0.4	0
52	Letter to the Editor. <i>Journal of Medical Economics</i> , 2014, 17, 248-249.	1.0	0
53	Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 221-221.	0.5	0
54	Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, S24-S31.	0.5	0

#	ARTICLE	IF	CITATIONS
55	An Umbrella Review of the Cost Effectiveness of Human Papillomavirus Vaccines. Clinical Drug Investigation, 2022, 42, 377.	1.1	0